Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03719430 · ClinicalTrials.gov registry record · Phase 2
APX005M and Doxorubicin in Advanced Sarcoma
A Phase 2 study of Soft Tissue Sarcoma, sponsored by Alexander Z. Wei, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 3
- Study locations
NCT03719430: Active Phase 2 study of Soft Tissue Sarcoma, sponsored by Alexander Z. Wei, MD.
NCT03719430 is a Phase 2 study of Soft Tissue Sarcoma that is active but no longer recruiting, run by Alexander Z. Wei, MD. The registered enrollment target is 27 participants, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (65% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03719430, a Phase 2 study of Soft Tissue Sarcoma, is active but no longer recruiting, sponsored by Alexander Z. Wei, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II clinical trial will evaluate the safety and efficacy of adding APX005M (a CD40 agonistic monoclonal antibody) to doxorubicin for the treatment of patients with advanced soft tissue sarcoma. The investigators believe that doxorubicin, which is currently the standard of care for most advanced sarcomas, could work better when combined with APX005M, which is a type of immunotherapy.
Primary Outcome
The percentage of patients achieving a partial or complete response as measured by imaging assessments from study treatment
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG APX005M
Study Locations (3)
California
- City of Hope - Duarte
Missouri
- Washington University School of Medicine - Siteman Cancer Center - St Louis
New York
- Columbia University Irving Medical Center/NYP - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2019-03-20 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What the registry record for NCT03719430 still lists
NCT03719430 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Doxorubicin is the first listed.
NCT03719430 reports a single indexed study location in California, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT03719430 about?
NCT03719430 is a clinical study titled "APX005M and Doxorubicin in Advanced Sarcoma". This phase II clinical trial will evaluate the safety and efficacy of adding APX005M (a CD40 agonistic monoclonal antibody) to doxorubicin for the treatment of patients with advanced soft tissue sarcoma. The investigators believe that doxorubicin, which is currently the standard of care for most adv...
What is the current status of trial NCT03719430?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2019-03-20. Estimated completion is 2026-12-31.
What conditions does trial NCT03719430 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma.
What interventions are being tested in trial NCT03719430?
The interventions under investigation include: Doxorubicin (DRUG), APX005M (DRUG).
Who is sponsoring clinical trial NCT03719430?
This trial is sponsored by Alexander Z. Wei, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03719430 being conducted?
This trial has 3 study locations across California, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03719430's enrollment target sits among peer trials
27 40th of 55 higher than 15 of 55 other Soft Tissue Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Soft Tissue Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
RECRUITING · Phase 2
-
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
RECRUITING · Phase 2
-
5-Day Preoperative Radiation for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI